Epigral, India’s integrated chemical major, reported revenue of Rs 6.15 billion for the quarter ended June 30, 2025, compared to Rs 6.54 billion in Q1FY25—a 6 per cent year-on-year decline, driven by softer volumes and lower realisations. Despite this, the company maintained a stable EBITDA margin of 27 per cent, supported by efficiency gains and an improved product mix. EBITDA stood at Rs 1.63 billion, a 7 per cent dip over the previous year.

Profit after tax (PAT) for the quarter stood at Rs 1.60 billion, benefiting from a Rs 810 million decrease in deferred tax liability. Excluding this, PAT was Rs 790 million versus Rs 860 million in the same quarter last year. Plant utilisation stood at 73 per cent during the quarter. The company’s return on capital employed (ROCE) improved to 24 per cent, up from 21 per cent a year ago, driven by better earnings, while Net Debt/EBITDA fell to 0.6x from 1.6x, reflecting stronger operating performance and deleveraging.

Revenue contribution from the Derivatives and Specialty Chemicals segment reached 50 per cent, and management expects this to rise further in coming quarters. Ongoing capex for CPVC and Epichlorohydrin capacity expansion remains on track in terms of budget and timeline. Additionally, the company plans to announce new investments for a remaining land parcel within its integrated complex.

Commenting on the performance, Maulik Patel, Chairman and Managing Director, said, “We expect H2FY26 to be stronger than H1FY26. Our focus on new chemistry aligned with import substitution will support high growth and strong ROCE. We continue to strengthen our integrated operations while pursuing scalable and profitable growth.”